{"data":{"briefTitle":"Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders","createdAt":{"_type":"Date","value":"Mon Nov 20 2023 21:16:21 GMT+0000 (Coordinated Universal Time)"},"criteriaText":"Inclusion Criteria:\n\n- Patients ages 18-70\n- Underlying hematological disorder which is potentially curable with allogeneic bone marrow transplantation. This includes, but is not limited to: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS), AL amyloidosis, diamond blackfan anemia, myelofibrosis or other myeloproliferative disease, sickle cell anemia, and thalassemia.\n- Existence of haploidentical first degree relative who passes standard donor evaluations for bone marrow and kidney donation\n- LVEF > 40% as measured by echocardiography or MUGA\n- FEV1, FVC, and DLCO > 50% of predicted as measured by standard PFTs\n- Total bilirubin < 2.0 (unless diagnosis of Gilbert's or hemolysis is made) and AST, ALT, alkaline phosphatase all < 5x institutions upper limit of normal\n- ABO compatibility in the host vs. graft direction\n- Men and women of reproductive potential must agree to use a reliable method of birth control during the treatment, and women should do so for a period of 1 year following the transplant.\n- Participants should be on dialysis or have an estimated or measured CrCl < 35 ml/min\n- Life expectancy greater than six months.\n- Recipient ability to understand and provide informed consent\n\nExclusion Criteria:\n\n- Active serious infection\n- Participation in other investigational drug use at the time of enrollment\n- Contraindication to therapy with any one of the proposed agents (e.g., history of allergy to rabbit serum in ATG)\n- Serologic positivity for HIV, HCV, or HbsAg positivity\n- ABO blood group incompatibility in the host-vs-graft direction\n- Active serious infection","criteriaTextDate":{"_type":"Date","value":"Mon Nov 20 2023 21:13:08 GMT+0000 (Coordinated Universal Time)"},"criteriaTree":{"id":"root","items":[{"id":"inclusion","items":[{"id":"group_7a62b389_5ff4_45fb_ab22_144ea55d74e2","items":[{"data":{"age":"18","operator":">=","relevantText":"- Patients ages 18-70","type":"ageRule"},"id":"rule_69bdedd9_63d9_435b_a15d_8e9399577719","operator":"AND","referenceText":"- Patients ages 18-70","type":"rule"},{"data":{"age":"70","operator":"<=","relevantText":"- Patients ages 18-70","type":"ageRule"},"id":"rule_615cefc8_549d_463d_a366_d34f6089c7ff","operator":"AND","referenceText":"- Patients ages 18-70","type":"rule"}],"lines":[2],"operator":"AND","text":"- Patients ages 18-70","type":"group"},{"id":"group_35403f55_5bb7_48a8_a7c4_6f21177a4548","items":[{"data":{"groups":[{"_type":"DocumentReference","path":"apps/curehub/groupedMappings/DCSvGG1t13BD5J6wtYw7"}],"operator":"INCLUDES_OR","relevantText":"- Underlying hematological disorder which is potentially curable with allogeneic bone marrow transplantation. This includes, but is not limited to: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS), AL amyloidosis, diamond blackfan anemia, myelofibrosis or other myeloproliferative disease, sickle cell anemia, and thalassemia.","resourceToUse":"groups","type":"conditionRule"},"id":"rule_d2f1a613_d56a_4620_bc09_0b6f06632f50","operator":"AND","referenceText":"- Underlying hematological disorder which is potentially curable with allogeneic bone marrow transplantation. This includes, but is not limited to: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS), AL amyloidosis, diamond blackfan anemia, myelofibrosis or other myeloproliferative disease, sickle cell anemia, and thalassemia.","type":"rule"}],"lines":[3],"operator":"AND","text":"- Underlying hematological disorder which is potentially curable with allogeneic bone marrow transplantation. This includes, but is not limited to: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS), AL amyloidosis, diamond blackfan anemia, myelofibrosis or other myeloproliferative disease, sickle cell anemia, and thalassemia.","type":"group"},{"id":"group_ba4c0d5a_f709_4cf3_814f_1df48e631c2f","items":[{"data":{"relevantText":"- Existence of haploidentical first degree relative who passes standard donor evaluations for bone marrow and kidney donation","type":"haploidenticalFirstDegreeRelativeForBoneMarrowAndKidneyDonationRule"},"id":"rule_13adc038_1412_4849_a8c9_4cefa63f4940","operator":"AND","referenceText":"- Existence of haploidentical first degree relative who passes standard donor evaluations for bone marrow and kidney donation","type":"rule"}],"lines":[4],"operator":"AND","text":"- Existence of haploidentical first degree relative who passes standard donor evaluations for bone marrow and kidney donation","type":"group"},{"id":"group_abfb88b1_14d2_4b26_9695_ef523663c1c0","items":[{"data":{"groups":[{"_type":"DocumentReference","path":"apps/curehub/groupedMappings/96LmiqpwaEOiS4HpsdEi"}],"min":40,"operator":"INCLUDES_OR","reason":"Dont know yet","relevantText":"- LVEF > 40% as measured by echocardiography or MUGA","resourceToUse":"groups","type":"observationRangeRule","unit":"%"},"id":"rule_0416cd44_b0c1_4bdb_b709_ac29fb56d317","operator":"AND","referenceText":"- LVEF > 40% as measured by echocardiography or MUGA","type":"rule"}],"lines":[5],"operator":"AND","text":"- LVEF > 40% as measured by echocardiography or MUGA","type":"group"},{"id":"group_21604875_265e_4556_8407_ef59847f44e0","items":[{"data":{"groups":[{"_type":"DocumentReference","path":"apps/curehub/groupedMappings/MxQSC7xBrik2YwcTuOmq"},{"_type":"DocumentReference","path":"apps/curehub/groupedMappings/Gj99hu1xNnpjVajgVEg2"},{"_type":"DocumentReference","path":"apps/curehub/groupedMappings/PNQ2OJLfWy6tVYsD03G0"}],"min":50,"operator":"INCLUDES_AND","reason":"dont know yet","relevantText":"- FEV1, FVC, and DLCO > 50% of predicted as measured by standard PFTs","resourceToUse":"groups","type":"observationRangeRule","unit":"%"},"id":"rule_6f59e65f_007e_4896_bbf2_53d3eef2a565","operator":"AND","referenceText":"- FEV1, FVC, and DLCO > 50% of predicted as measured by standard PFTs","type":"rule"}],"lines":[6],"operator":"AND","text":"- FEV1, FVC, and DLCO > 50% of predicted as measured by standard PFTs","type":"group"},{"id":"group_49a7a23a_153a_42f2_b999_8e5efcbb469f","items":[{"id":"group_87444a19_2ab9_44ce_a534_607d5eba0da2","items":[{"data":{"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/27503000"},{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/73320003"}],"operator":"INCLUDES_OR","relevantText":"- diagnosis of Gilbert's or hemolysis is made","resourceToUse":"mappings","type":"conditionRule"},"id":"rule_22226705_e081_4622_9d2c_10f1e0a72e32","operator":"AND","referenceText":"- Total bilirubin < 2.0 (unless diagnosis of Gilbert's or hemolysis is made) and AST, ALT, alkaline phosphatase all < 5x institutions upper limit of normal","type":"rule"},{"data":{"groups":[{"_type":"DocumentReference","path":"apps/curehub/groupedMappings/gYOav3dZILCJ7LFjMT0X"}],"max":2,"operator":"INCLUDES_OR","relevantText":"- Total bilirubin < 2.0","resourceToUse":"groups","type":"observationRangeRule","unitNotRequired":true},"id":"rule_530e7161_7769_4c43_ad66_272da587cce8","operator":"AND","referenceText":"- Total bilirubin < 2.0 (unless diagnosis of Gilbert's or hemolysis is made) and AST, ALT, alkaline phosphatase all < 5x institutions upper limit of normal","type":"rule"}],"operator":"OR","type":"group"},{"data":{"factor":5,"groups":[{"_type":"DocumentReference","path":"apps/curehub/groupedMappings/5XjhFWPBdaekYWSZuLwJ"},{"_type":"DocumentReference","path":"apps/curehub/groupedMappings/wYcSCCl9dqUhLUcbvQCf"},{"_type":"DocumentReference","path":"apps/curehub/groupedMappings/vuFeuOfOsQhGEhk8EFou"}],"limit":"Upper","operator":"<","relevantText":"- AST, ALT, alkaline phosphatase all < 5x institutions upper limit of normal","resourceToUse":"groups","type":"observationUpperLowerLimits"},"id":"rule_1203942c_ceea_477b_8862_5feb7d2f9b22","operator":"AND","referenceText":"- Total bilirubin < 2.0 (unless diagnosis of Gilbert's or hemolysis is made) and AST, ALT, alkaline phosphatase all < 5x institutions upper limit of normal","type":"rule"}],"lines":[7],"operator":"AND","text":"- Total bilirubin < 2.0 (unless diagnosis of Gilbert's or hemolysis is made) and AST, ALT, alkaline phosphatase all < 5x institutions upper limit of normal","type":"group"},{"id":"group_63f56764_d27f_4ea1_8207_79cc9857edd9","items":[{"data":{"reason":"dont know yet","relevantText":"- ABO compatibility in the host vs. graft direction","type":"verifyDuringScreeningByDoctorRule"},"id":"rule_bb68c38c_c022_475d_998c_bed616b69101","operator":"AND","referenceText":"- ABO compatibility in the host vs. graft direction","type":"rule"}],"lines":[8],"operator":"AND","text":"- ABO compatibility in the host vs. graft direction","type":"group"},{"id":"group_bb63096e_5b13_4f10_aad4_27bddf75057d","items":[{"data":{"relevantText":"- Men and women of reproductive potential must agree to use a reliable method of birth control during the treatment, and women should do so for a period of 1 year following the transplant.","type":"willingToPracticeBirthcontrolRule"},"id":"rule_f3fa2190_6a7b_46f6_a0ae_6ec00158976b","operator":"AND","referenceText":"- Men and women of reproductive potential must agree to use a reliable method of birth control during the treatment, and women should do so for a period of 1 year following the transplant.","type":"rule"}],"lines":[9],"operator":"AND","text":"- Men and women of reproductive potential must agree to use a reliable method of birth control during the treatment, and women should do so for a period of 1 year following the transplant.","type":"group"},{"id":"group_5a90fb89_b0a9_4fcb_8048_a35639c1756f","items":[{"data":{"mappings":[{"_type":"DocumentReference","path":"apps/curehub/procedureMappings/1231460007"}],"operator":"INCLUDES_OR","relevantText":"- Participants should be on dialysis or have an estimated or measured CrCl < 35 ml/min","resourceToUse":"mappings","type":"procedureRule"},"id":"rule_24703bff_01a0_4461_b079_6a733b22038e","operator":"AND","referenceText":"- Participants should be on dialysis or have an estimated or measured CrCl < 35 ml/min","type":"rule"},{"data":{"mappings":[{"_type":"DocumentReference","path":"apps/curehub/observationMappings/11041-1"}],"max":35,"operator":"INCLUDES_OR","relevantText":"Have an estimated or measured CrCl < 35 ml/min","resourceToUse":"mappings","type":"observationRangeRule","unit":"ml/min"},"id":"rule_73150018_40e6_4991_a2d3_e8bc37652215","operator":"AND","referenceText":"- Participants should be on dialysis or have an estimated or measured CrCl < 35 ml/min","type":"rule"}],"lines":[10],"operator":"OR","text":"- Participants should be on dialysis or have an estimated or measured CrCl < 35 ml/min","type":"group"},{"id":"group_c1a43891_0b90_48b8_b371_6a8c395541d2","items":[{"data":{"min":6,"relevantText":"- Life expectancy greater than six months.","type":"lifeExpectancyMonthsRangeRule"},"id":"rule_ad07ddf4_57a5_441e_8511_979eb857d1b9","operator":"AND","referenceText":"- Life expectancy greater than six months.","type":"rule"}],"lines":[11],"operator":"AND","text":"- Life expectancy greater than six months.","type":"group"},{"id":"group_0e0c268b_5bbd_49ad_857a_fc991854778b","items":[{"data":{"relevantText":"- Recipient ability to understand and provide informed consent","type":"consentRule"},"id":"rule_eefe84df_7248_4abc_8f99_0c56a7592bd0","operator":"AND","referenceText":"- Recipient ability to understand and provide informed consent","type":"rule"}],"lines":[12],"operator":"AND","text":"- Recipient ability to understand and provide informed consent","type":"group"}],"operator":"AND","type":"group"},{"id":"exclusion","items":[{"id":"group_9b18a8fc_3ae0_4494_9f29_dc21d850192c","items":[{"data":{"groups":[{"_type":"DocumentReference","path":"apps/curehub/groupedMappings/pELkTac76HQaPcmNfyqE"}],"operator":"INCLUDES_OR","relevantText":"- Active serious infection","resourceToUse":"groups","type":"conditionRule"},"id":"rule_5bb95766_581a_45b0_96e1_cb5de98c4d39","operator":"AND","referenceText":"- Active serious infection","type":"rule"}],"lines":[16],"operator":"AND","text":"- Active serious infection","type":"group"},{"id":"group_c891cbfa_ce56_4ec1_b1d4_ee661099402e","items":[{"data":{"relevantText":"- Participation in other investigational drug use at the time of enrollment","type":"clinicalTrialRule"},"id":"rule_1f6b3907_a276_4e19_bc11_9e205a1c76fc","operator":"AND","referenceText":"- Participation in other investigational drug use at the time of enrollment","type":"rule"}],"lines":[17],"operator":"AND","text":"- Participation in other investigational drug use at the time of enrollment","type":"group"},{"id":"group_c4f2d22f_d9dc_42f7_9ccf_7dc9085c8251","items":[{"data":{"reason":"There is no rule for contraindication for any medication","relevantText":"- Contraindication to therapy with any one of the proposed agents (e.g., history of allergy to rabbit serum in ATG)","type":"verifyDuringScreeningByDoctorRule"},"id":"rule_6a77d350_89f1_4c63_a385_fcfc8d1093f6","operator":"AND","referenceText":"- Contraindication to therapy with any one of the proposed agents (e.g., history of allergy to rabbit serum in ATG)","type":"rule"}],"lines":[18],"operator":"AND","text":"- Contraindication to therapy with any one of the proposed agents (e.g., history of allergy to rabbit serum in ATG)","type":"group"},{"id":"group_b1fbf1ca_d7a5_4e4e_9e86_88b8b27cdae9","items":[{"data":{"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/62944002"},{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/81665004"},{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/19030005"}],"operator":"INCLUDES_OR","relevantText":"- Serologic positivity for HIV, HCV, or HbsAg positivity","resourceToUse":"mappings","type":"conditionRule"},"id":"rule_555f9e0c_7e3d_4121_be19_e9ef44366e70","operator":"AND","referenceText":"- Serologic positivity for HIV, HCV, or HbsAg positivity","type":"rule"}],"lines":[19],"operator":"AND","text":"- Serologic positivity for HIV, HCV, or HbsAg positivity","type":"group"},{"id":"group_8d2bdd65_40c7_469d_8bc6_42f747b6226f","items":[{"data":{"reason":"dont know yet","relevantText":"- ABO blood group incompatibility in the host-vs-graft direction","type":"verifyDuringScreeningByDoctorRule"},"id":"rule_dc95f087_da18_4766_a5f4_1eee7bd4b6c5","operator":"AND","referenceText":"- ABO blood group incompatibility in the host-vs-graft direction","type":"rule"}],"lines":[20],"operator":"AND","text":"- ABO blood group incompatibility in the host-vs-graft direction","type":"group"}],"operator":"OR","type":"group"}],"operator":"AND","type":"group"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"}],"nctId":"NCT01758042","status":"COMPLETED","updatedAt":{"_type":"Date","value":"Wed Nov 22 2023 21:22:58 GMT+0000 (Coordinated Universal Time)"},"user":{"_type":"DocumentReference","path":"users/9O8yW1YPXeatKI6ECdMXjubU6r63"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/curehub/labeledClinicalTrialsCriteria/NCT01758042"},"snapshot":{"exists":true,"id":"NCT01758042","ref":{"_type":"DocumentReference","path":"apps/curehub/labeledClinicalTrialsCriteria/NCT01758042"}}}